ViaNautis develops polyNaut®, a proprietary nanovesicle platform that utilizes advanced polymer materials and machine learning to deliver nucleic acid therapeutics with high precision to targeted tissues and cell types. This technology addresses the challenge of safely and effectively delivering genetic medicines, such as mRNA and siRNA, to treat previously untreatable diseases.
Funding
$28.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Effective delivery of nucleic acid therapeutics, such as mRNA and siRNA, to specific tissues and cell types remains a significant challenge. Existing methods often lack the precision needed to target the intended site of action, limiting their therapeutic potential. This can result in off-target effects and reduced efficacy in treating previously untreatable diseases.
Solution
ViaNautis is developing polyNaut®, a proprietary nanovesicle platform designed for precise delivery of nucleic acid therapeutics. The platform utilizes advanced polymer materials and machine learning to direct genetic molecules to their intended sites of action with enhanced precision. By leveraging non-immunogenic polyNaut® nanovesicles, the technology aims to improve the safety and efficacy of genetic medicines. This targeted approach enables the development of novel therapeutics for diseases that were previously difficult to treat.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing genetic medicines and advanced therapeutics.
Features
- Proprietary polyNaut® nanovesicle platform for targeted drug delivery
- Utilizes advanced polymer materials for enhanced biocompatibility and stability
- Employs machine learning for in silico screening and precise targeting of specific tissues and cell types
- Designed for delivery of various nucleic acid therapeutics, including mRNA and siRNA
- Non-immunogenic properties to minimize adverse immune responses